-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
-
-
-
-
-
-
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
-
-
-
-
-
-
FDA accepts Ionis' olezarsen application for priority review
-
-
-
-
-
-
-
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
-
-
-
-
-
-
-
Ionis reports fourth quarter and full year 2024 financial results
-
-
-
-
-
-
-
Ionis Pharmaceuticals (IONS) announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
-
-
-
-
-
-
-
Ionis Pharmaceuticals (IONS) Expands eplontersen Deal with AstraZeneca (AZN) to Include Latin America
-
15,546 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

